185 related articles for article (PubMed ID: 29628024)
1. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
Liao K; Liu Y; Ai CZ; Yu X; Li W
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
[TBL] [Abstract][Full Text] [Related]
2. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
Ortega-Vázquez A; Dorado P; Fricke-Galindo I; Jung-Cook H; Monroy-Jaramillo N; Martínez-Juárez IE; Familiar-López I; Peñas-Lledó E; LLerena A; López-López M
Pharmacogenomics J; 2016 Jun; 16(3):286-92. PubMed ID: 26122019
[TBL] [Abstract][Full Text] [Related]
3. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
[TBL] [Abstract][Full Text] [Related]
4. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
5. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Ikeda H; Ueda Y; Yamaguchi T; Nasu H; Ohtani H; Shigematsu H; Kagawa Y; Inoue Y
Ther Drug Monit; 2015 Apr; 37(2):229-35. PubMed ID: 25162219
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.
Kesavan R; Narayan SK; Adithan C
Eur J Clin Pharmacol; 2010 Jul; 66(7):689-96. PubMed ID: 20390258
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
Franco V; Perucca E
Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
[TBL] [Abstract][Full Text] [Related]
8. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of effects of
Kanjanasilp J; Sawangjit R; Phanthaisong S; Borihanthanawuth W
Pharmacogenomics; 2021 Jul; 22(10):629-640. PubMed ID: 34060344
[No Abstract] [Full Text] [Related]
10. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients.
Hung CC; Huang HC; Gao YH; Chang WL; Ho JL; Chiou MH; Hsieh YW; Liou HH
Pharmacogenomics; 2012 Sep; 13(12):1339-49. PubMed ID: 22966884
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
[TBL] [Abstract][Full Text] [Related]
12. Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.
Fohner AE; Rettie AE; Thai KK; Ranatunga DK; Lawson BL; Liu VX; Schaefer CA
Clin Transl Sci; 2020 Sep; 13(5):1004-1009. PubMed ID: 32216088
[TBL] [Abstract][Full Text] [Related]
13. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
[TBL] [Abstract][Full Text] [Related]
14. The effect of polymorphic metabolism enzymes on serum phenytoin level.
Ozkaynakci A; Gulcebi MI; Ergeç D; Ulucan K; Uzan M; Ozkara C; Guney I; Onat FY
Neurol Sci; 2015 Mar; 36(3):397-401. PubMed ID: 25311916
[TBL] [Abstract][Full Text] [Related]
15. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
Lee SY; Lee ST; Kim JW
J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
[TBL] [Abstract][Full Text] [Related]
17. A real-life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy.
Riva A; Roberti R; D'Onofrio G; Vari MS; Amadori E; De Giorgis V; Cerminara C; Specchio N; Pietrafusa N; Tombini M; Assenza G; Cappanera S; Marini C; Rasmini P; Veggiotti P; Zara F; Russo E; Striano P
Epilepsia Open; 2023 Sep; 8(3):1142-1150. PubMed ID: 36840436
[TBL] [Abstract][Full Text] [Related]
18. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
[TBL] [Abstract][Full Text] [Related]
19. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
20. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
